Antibodies and related products are the fastest growing class of therapeutic agents. By analysing the regulatory approvals of IgG-based biotherapeutic agents in the past 10 years, we can gain ...

In this part of his Pharmaceutical Executive video interview, Ian Chan, CEO of Abpro discusses the advantages of their DiversImmune and MultiMab platforms for antibody discovery and engineering.

The Vancouver-based company uses generative AI to create biologic drugs, with 20 “active programs” underway, many of them ...

Ellipses Pharma Limited ("Ellipses"), a global drug development company focused on accelerating the development of cancer treatments through an innovative drug development model, announced today it is ...

As more and more combinations of antibodies are being developed to treat complex diseases, the generation of a product consisting of several mono- or bispecific antibodies represents an attractive ...

In this episode of Talking Techniques, we speak to two experts from Sino Biological US Inc. (PA, USA) about the latest developments in antibody technologies and how these developments have led to the ...

The researchers say antibodies in this class are particularly ... The approach used in this study could also aid the development of a new generation of countermeasures against other pathogens ...